|Detection of CD79B in Mouse Splenocytes by Flow Cytometry. Mouse splenocytes were stained with Rat Anti-Mouse CD79B Monoclonal Antibody (Catalog # MAB6814) followed by Allophycocyanin-conjugated Anti-Rat IgG Secondary Antibody (Catalog # F0113) and Rat Anti-Mouse B220/CD45R PE-conjugated Monoclonal Antibody (Catalog # FAB1217P). Quadrant markers were set based on control antibody staining (Catalog # MAB006).|
CD79B in Mouse Splenocytes. |
CD79B was detected in immersion fixed mouse splenocytes using Rat Anti-Mouse CD79B Monoclonal Antibody (Catalog # MAB6814) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (red, upper panel; Catalog # NL013) and counterstained with DAPI (blue, lower panel). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta -chain) is a 37-39 kDa member of the Ig-Superfamily. It is expressed on B cells and forms a covalent heterodimer with CD79A. This complex interacts noncovalently with membrane Ig, forming the B cell antigen receptor. Within this complex, membrane Ig detects antigen while CD79A:B initiates signaling. CD79B is also required for formation of pre-B cells during B cell development. Mature mouse CD79B is a 203 amino acid (aa) type I transmembrane glycoprotein (aa 26-228). It contains an extracellular region with one V-type Ig-like domain (aa 41-132) and an ITAM‑containing cytoplasmic domain (aa 181-228). CD79B may migrate as two bands in SDS-PAGE. One defines the standard 37 kDa form, while a second represents one of two possible isoforms, the first of which is an underglycosylated full-length CD79B, and the second of which is an alternative splice form that likely lacks the C‑terminal 32 amino acids. Mouse CD79A and CD79B share only 24% aa identity. Over aa 29-158, mouse CD79B shares 54% and 78% aa identity with human and rat CD79B, respectively.